{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple+Negative+Breast+Cancer+Patients&page=5", "query": { "condition": "Triple Negative Breast Cancer Patients", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 436, "total_pages": 44, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple+Negative+Breast+Cancer+Patients&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple+Negative+Breast+Cancer+Patients&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T06:42:48.113Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06562192", "title": "Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer", "HR+/HER2- Ductal and Lobular Breast Cancer", "Triple Negative Breast Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "[68Ga]Ga-NNS309", "type": "DRUG" }, { "name": "[177Lu]Lu-NNS309", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 162, "start_date": "2024-10-15", "completion_date": "2031-01-16", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06562192" }, { "nct_id": "NCT04461600", "title": "A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "AL101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ayala Pharmaceuticals, Inc,", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2020-08-14", "completion_date": "2022-10-11", "has_results": true, "last_update_posted_date": "2024-02-12", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 17, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • San Francisco, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04461600" }, { "nct_id": "NCT03076372", "title": "A Study Evaluating MM-310 in Patients With Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Urothelial Carcinoma", "Gastric Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Ovarian Cancer", "Pancreatic Ductal Adenocarcinoma", "Prostate Adenocarcinoma", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Triple Negative Breast Cancer", "Endometrial Carcinoma", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "MM-310", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2017-02-22", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2018-02-27", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03076372" }, { "nct_id": "NCT05112536", "title": "Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Cylophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin (Investigator discretion)", "type": "DRUG" }, { "name": "Pembrolizumab (Investigator discretion)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2022-03-03", "completion_date": "2023-03-13", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 7, "location_summary": "Los Alamitos, California • Santa Monica, California • Whittier, California + 4 more", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05112536" }, { "nct_id": "NCT02792114", "title": "T-Cell Therapy for Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Metastatic HER2-negative Breast" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesothelin-targeted T cells", "type": "BIOLOGICAL" }, { "name": "AP1903", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 186, "start_date": "2016-06", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02792114" }, { "nct_id": "NCT03875313", "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Clear Cell Renal Cell Carcinoma", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer", "CRC", "RCC", "ccRCC" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-05-20", "completion_date": "2020-07-29", "has_results": true, "last_update_posted_date": "2022-02-17", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03875313" }, { "nct_id": "NCT04099277", "title": "A Study of LY3435151 in Participants With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Triple-negative Breast Cancer", "Gastric Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma", "Cervical Carcinoma", "High Grade Serous Ovarian Carcinoma", "Hepatocellular Carcinoma", "Undifferentiated Pleomorphic Sarcoma", "Leiomyosarcoma" ], "interventions": [ { "name": "LY3435151", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-10-28", "completion_date": "2020-03-05", "has_results": true, "last_update_posted_date": "2021-08-31", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04099277" }, { "nct_id": "NCT00817531", "title": "Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Breast Care Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 22, "start_date": "2008-12", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2012-08-31", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00817531" }, { "nct_id": "NCT00861705", "title": "Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Male Breast Carcinoma", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 454, "start_date": "2009-07-21", "completion_date": "2025-09-02", "has_results": true, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 448, "location_summary": "Jonesboro, Arkansas • Rogers, Arkansas • Berkeley, California + 309 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861705" }, { "nct_id": "NCT03742102", "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 243, "start_date": "2018-12-21", "completion_date": "2027-02-26", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-12T06:42:48.113Z", "location_count": 8, "location_summary": "Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03742102" } ] }